Addiction

William F. Peacock, MD; Conar Fitton, MD; and Neel Mehta, MD, discuss the multidisciplinary approaches to selecting therapies for patients with opioid-induced constipation.

A multidisciplinary panel shares practical approaches to treating patients with opioid-induced constipation and challenges with patient communication.

Buprenorphine has shown to be effective and has the potential for widespread use to address the opioid epidemic. A subset of individuals with OUD have been acquiring it without a prescription.

An Ohio State researcher discusses a new medical center education program for navigating addiction risk in pain patients.

William F. Peacock, MD; Conar Fitton, MD; and Neel Mehta, MD, reviews the position of pharmacies in providing patients with opioid-induced constipation with the necessary medication to decrease hospitalization and cost of medication.

Experts in gastroenterology discuss the quality of life and perspective of patients with opioid-induced constipation.

Varenicline was efficacious at weeks 12, 24, and 52 of the trial compared with placebo in a smoking cessation program.

During the analysis, investigators became fascinated by how many patients entered the buprenorphine treatment program for OUD having already been taking the drug without a prescription.

William F. Peacock, MD; Conar Fitton, MD; and Neel Mehta, MD, explore the importance of early intervention and the overall challenges of ensuring that patients receive appropriate care for opioid-induced constipation.

A multidisciplinary panel discusses the presentation, frequency, and burden of opioid-induced constipation.

Dr William F. Peacock shares clinical pearls for the management of opioid-induced constipation.

Intravenous opioid use for VOC decreased by 52% in inpatient services between 2017-2018, while oral opioid use increased.

While young adults may be resistant to drinking interventions, improving sleep behavior can indirectly reduce hazardous drinking.

Since the delivery of these medications were disrupted during the pandemic, members of racial and ethnic minority groups experienced an increased risk of opioid overdose, compared with White individuals.

The director of NIDA discusses the unprecedented impact of the pandemic on overdose deaths—and how substance use disorder care may still reach greater capability when all is said and done.